QuidelOrtho Corp (QDEL): Shareholders' Equity

Annual figures by period end, from SEC filings.

$1.92B
As of 2025-12-28
$1.77B
As of 2026-06-28
-27.0%
3-year compound annual growth
+7.6%
5-year compound annual growth
$5.01B2021-01-03: $1.33B2022-01-02: $1.93B2023-01-01: $4.93B2023-12-31: $5.01B2024-12-29: $2.98B2025-12-28: $1.92B$1.92B
2021-01-03 Shareholders' Equity (USD) 2025-12-28
Period endedShareholders' EquityChange YoYSource filing
2025-12-28$1.92B-35.7%2026-02-19, Balance as of period end
2024-12-29$2.98B-40.4%2026-02-19, Balance as of period end
2023-12-31$5.01B+1.4%2026-02-19, Balance as of period end
2023-01-01, Fiscal 2022$4.93B+155.8%2025-02-27, Balance as of period end
2022-01-02, Fiscal 2021$1.93B+44.8%2024-08-01, Balance as of period end
2021-01-03, Fiscal 2020$1.33Bn/a2023-02-23, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
QuidelOrtho Corp (QDEL)2025-12-28$1.92B-35.7%
Idexx Laboratories Inc (IDXX)2025-12-31$1.61B+0.6%
Lantheus Holdings, Inc. (LNTH)2025-12-31$1.09B+0.2%
Neogen Corp (NEOG)2026-05-31$2.09B+1.0%
Myriad Genetics Inc (MYGN)2025-12-31$368.00M-47.5%
Intellia Therapeutics, Inc. (NTLA)2025-12-31$671.39M-23.0%
Alpha Teknova, Inc. (TKNO)2025-12-31$68.78M-16.5%
Immucell Corp (ICCC)2025-12-31$27.06M-1.7%
Aspira Women's Health Inc. (AWHL)2025-12-31-$6.93Mn/m

Compare QDEL, IDXX, LNTH, NEOG side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗